Prime Medicine, Inc.
PRME · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.08 | 0.35 | -0.00 |
| FCF Yield | -37.58% | -21.61% | -8.19% | -3.83% |
| EV / EBITDA | -1.04 | -4.02 | -14.87 | -5.11 |
| Quality | ||||
| ROIC | -76.94% | -122.47% | -32.15% | -32.58% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.63 | 0.83 | 1.08 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | 25.25% | -17.72% | -286.91% | -518.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.72 | 0.14 | 1.43 | 1.09 |
| Interest Coverage | 0.00 | 0.00 | -9.61 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -676.10 | -1,532.56 | -131.61 | -107.75 |